165 related articles for article (PubMed ID: 23785231)
1. Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy.
Tlucek PS; Folk JC; Sobol WM; Mahajan VB
Clin Ophthalmol; 2013; 7():1093-8. PubMed ID: 23785231
[TBL] [Abstract][Full Text] [Related]
2. Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy.
Cham A; Bansal M; Banda HK; Kwon Y; Tlucek PS; Bassuk AG; Tsang SH; Sobol WM; Folk JC; Yeh S; Mahajan VB
Clin Ophthalmol; 2016; 10():1187-97. PubMed ID: 27390515
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy.
Tlucek PS; Folk JC; Orien JA; Stone EM; Mahajan VB
Arch Ophthalmol; 2012 Nov; 130(11):1395-401. PubMed ID: 22777573
[TBL] [Abstract][Full Text] [Related]
4. Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes.
Randazzo NM; Shanks ME; Clouston P; MacLaren RE
Ocul Immunol Inflamm; 2019; 27(5):693-698. PubMed ID: 29040051
[No Abstract] [Full Text] [Related]
5. Lymphocyte infiltration in CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy.
Mahajan VB; Lin JH
Clin Ophthalmol; 2013; 7():1339-45. PubMed ID: 23861576
[TBL] [Abstract][Full Text] [Related]
6. Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy.
Rowell HA; Bassuk AG; Mahajan VB
Clin Ophthalmol; 2012; 6():2037-44. PubMed ID: 23271883
[TBL] [Abstract][Full Text] [Related]
7. Autosomal dominant neovascular inflammatory vitreoretinopathy with CAPN5 c.731T > C gene mutation; clinical management of a family cohort and review of the literature.
Tabbaa T; Mehra AA; Kesav NP; Mahajan VB; Swanson RD; Zubricky R; Sobol WM
Ophthalmic Genet; 2023 Dec; 44(6):559-567. PubMed ID: 37782277
[TBL] [Abstract][Full Text] [Related]
8. Early-onset Neovascular Inflammatory Vitreoretinopathy Due to Two de Novo CAPN5 Mutations in Chinese Patients: A Case Series.
Xia FJ; Lyu J; Zhang X; Fei P; Zhao PQ
Ocul Immunol Inflamm; 2023 Nov; 31(9):1777-1784. PubMed ID: 36369866
[TBL] [Abstract][Full Text] [Related]
9. Early Onset Neovascular Inflammatory Vitreoretinopathy Due to a
O'Keefe G; Hanif AM; Mahajan VB; Jain N
Ocul Immunol Inflamm; 2019; 27(5):706-708. PubMed ID: 30986125
[TBL] [Abstract][Full Text] [Related]
10. Structural modeling of a novel CAPN5 mutation that causes uveitis and neovascular retinal detachment.
Bassuk AG; Yeh S; Wu S; Martin DF; Tsang SH; Gakhar L; Mahajan VB
PLoS One; 2015; 10(4):e0122352. PubMed ID: 25856303
[TBL] [Abstract][Full Text] [Related]
11. Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina.
Wert KJ; Skeie JM; Bassuk AG; Olivier AK; Tsang SH; Mahajan VB
Hum Mol Genet; 2014 May; 23(10):2665-77. PubMed ID: 24381307
[TBL] [Abstract][Full Text] [Related]
12. Ultra-widefield Fluorescein Angiography and OCT Findings in Children and Young Adults with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV).
Ebert JJ; Maccora I; Sapp CC; Nguyen T; Sisk RA; Srivastava SK; Angeles-Han ST; Sood AB
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38782117
[TBL] [Abstract][Full Text] [Related]
13. Photoreceptor Cell-Derived CAPN5 Regulates Retinal Pigment Epithelium Cell Proliferation Through Direct Regulation of SLIT2 Cleavage.
Wang Y; Li H; Zang S; Li F; Chen Y; Zhang X; Song Z; Peng Q; Gu F
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1810-1821. PubMed ID: 29610848
[TBL] [Abstract][Full Text] [Related]
14. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
Arcinue CA; Cerón OM; Foster CS
J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
[TBL] [Abstract][Full Text] [Related]
15. CAPN5 gene silencing by short hairpin RNA interference.
Nelson NG; Skeie JM; Muradov H; Rowell HA; Seo S; Mahajan VB
BMC Res Notes; 2014 Sep; 7():642. PubMed ID: 25216694
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic variance in Calpain-5 retinal degeneration.
Tang PH; Chemudupati T; Wert KJ; Folk JC; Mahajan M; Tsang SH; Bassuk AG; Mahajan VB
Am J Ophthalmol Case Rep; 2020 Jun; 18():100627. PubMed ID: 32274441
[TBL] [Abstract][Full Text] [Related]
17. CAPN5 mutation in hereditary uveitis: the R243L mutation increases calpain catalytic activity and triggers intraocular inflammation in a mouse model.
Wert KJ; Bassuk AG; Wu WH; Gakhar L; Coglan D; Mahajan M; Wu S; Yang J; Lin CS; Tsang SH; Mahajan VB
Hum Mol Genet; 2015 Aug; 24(16):4584-98. PubMed ID: 25994508
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery.
Nicholson BP; Singh RP; Sears JE; Lowder CY; Kaiser PK
Am J Ophthalmol; 2012 Dec; 154(6):969-973.e1. PubMed ID: 22981365
[TBL] [Abstract][Full Text] [Related]
19. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous dislocation of a fluocinolone acetonide implant (Retisert) into the anterior chamber and its successful extraction in sympathetic ophthalmia.
Almeida DR; Chin EK; Mears K; Russell SR; Mahajan VB
Retin Cases Brief Rep; 2015; 9(2):142-4. PubMed ID: 25411930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
